To offer you a better experience, this site uses cookies, including those of third parties. To find out more and manage your preferences, consult the cookie policy
Though it may start as an isolated tumor of the eye,
becoming a systemic disease.1
As metastatic UM (mUM) runs its course, treatment options are limited and patients face a median survival of up to 12 months.2 So, when you see mUM, think fast.
Presentation and symptoms, risk factors and management
Intrinsic differences between UM and cutaneous melanoma (CM)
Clinical perspectives and resources for patients and caregivers
The information contained on this website is intended for healthcare professionals. By clicking the "Continue" button, you are acknowledging that you are a healthcare professional.
The information and other content contained on this website are not intended to be, nor should they be, used as medical advice, diagnosis, or treatment. Each patient must be evaluated, diagnosed, and treated based upon that individual patient's specific circumstances.
Click “Continue” to proceed to an external website not sponsored or controlled by Immunocore.
Select “Cancel” to return to ThinkUvealMelanoma.com.
You will be notified when new information becomes available at ThinkUvealMelanoma.com.
You have been unsubscribed from ThinkUvealMelanoma.com.